TIDMINC

RNS Number : 4987V

Incanthera PLC

05 April 2023

5 April 2023

Incanthera plc

("Incanthera" or the "Company")

Result of Warrant Holder Meeting

Incanthera plc is pleased to confirm that, at a meeting of Warrant Holders held today, both resolutions put to the meeting in respect of the extension to the duration and exercise price of the warrants were passed.

Accordingly, the terms of the warrants issued in conjunction with the fundraising announced on 23 March 2021, have been amended such that they now expire on 12 April 2024 and have an exercise price of 10p.

For further enquiries:

Incanthera plc:

 
 www.incanthera.com 
 
  Tim McCarthy, Chairman tim.mccarthy@incanthera.com                        +44 (0) 7831 675747 
 
  Simon Ward, Chief Executive Officer simon.ward@incanthera.com             +44 (0) 7747 625506 
 
  Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com      +44 (0) 7776 234600 
 
 AQSE Corporate Adviser: 
  Cairn Financial Advisers LLP 
  Jo Turner/Ludo Lazzaretti                                               +44 (0) 20 7213 0880 
 
 Broker: 
  Stanford Capital Partners Ltd 
  Patrick Claridge/Tom Price/John Howes/Bob Pountney                      +44 (0) 20 3650 3650

Notes to Editors

Incanthera is dedicated to innovative technologies in dermatology and oncology. It seeks to identify and commercialise inspirational therapeutics combined with uniquely targeted delivery systems, for innovative solutions to clinical, commercially relevant unmet needs.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. The Company is currently focussed upon delivering Sol to a commercial partner.

Originating from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford, the Company has acquired and developed a portfolio of specific cancer-targeting therapeutics, with a strategy to develop each candidate from initial acquisition/discovery to commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com

@incantheraplc

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXGZGGDMKMGFZM

(END) Dow Jones Newswires

April 05, 2023 07:04 ET (11:04 GMT)

Incanthera (AQSE:INC)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025 Plus de graphiques de la Bourse Incanthera
Incanthera (AQSE:INC)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025 Plus de graphiques de la Bourse Incanthera